마이코플라스마 폐렴에서 조기 스테로이드 사용의 유용성
Efficacy of early steroid use in Mycoplasma pneumoniae pneumonia
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to evaluate whether or not the early use of steroid is useful for treating Mycoplasma pneumoniae pneumonia. Methods: A prospective study was conducted on 85 patients with M. pneumoniae pneumonia admitted to Gwangju Christian Hospital between September 2015 and April 2016. A total of 85 patients were enrolled. Of these, 33 were treated with steroids (methylprednisolone 1 mg/kg/day), while 52 were not; both were treated with macrolides. The overall duration of fever was compared between the 2 groups and findings on chest radiographs were evaluated for their deterioration. Results: The duration of fever after admission (1.36±0.92 days vs. 2.17±1.30 days, P=0.003) and the overall duration of fever (4.42±2.13 days vs. 6.07±2.59 days, P=0.003) were significantly lower in the steroid group. The duration of fever before admission was not different between the steroid and macrolide groups (3.06±1.74 days vs. 3.90±2.21 days, P=0.068). On chest radiographs taken 3 days later, 1 of 33 patients in the steroid group and 5 of 50 patients in the macrolide group worsened, although there was no statistically significant difference between the 2 groups (P=0.395). There was no significant difference in the duration of hospitalization between the 2 groups (6.72±1.54 days vs. 6.92±1.87 days, P=0.618). Conclusion: Early administration of steroids on patients with M. pneumoniae pneumonia reduced the duration of fever, but there was no difference in duration of admission and x-ray deterioration.
Abstract
Purpose: The aim of this study was to evaluate whether or not the early use of steroid is useful for treating Mycoplasma pneumoniae pneumonia. Methods: A prospective study was conducted on 85 patients with M. pneumoniae pneumonia admitted to Gwangju Christian Hospital between September 2015 and April 2016. A total of 85 patients were enrolled. Of these, 33 were treated with steroids (methylprednisolone 1 mg/kg/day), while 52 were not; both were treated with macrolides. The overall duration of fever was compared between the 2 groups and findings on chest radiographs were evaluated for their deterioration. Results: The duration of fever after admission (1.36±0.92 days vs. 2.17±1.30 days, P=0.003) and the overall duration of fever (4.42±2.13 days vs. 6.07±2.59 days, P=0.003) were significantly lower in the steroid group. The duration of fever before admission was not different between the steroid and macrolide groups (3.06±1.74 days vs. 3.90±2.21 days, P=0.068). On chest radiographs taken 3 days later, 1 of 33 patients in the steroid group and 5 of 50 patients in the macrolide group worsened, although there was no statistically significant difference between the 2 groups (P=0.395). There was no significant difference in the duration of hospitalization between the 2 groups (6.72±1.54 days vs. 6.92±1.87 days, P=0.618). Conclusion: Early administration of steroids on patients with M. pneumoniae pneumonia reduced the duration of fever, but there was no difference in duration of admission and x-ray deterioration.
참고문헌 (26)
- Chen ZR, "Epidemiology of community-acquired Mycoplasma Pneumoniae respiratory tract infections among hospitalized Chinese children, including relationships with meteorological factors", Hippokratia, 17, pp.20~26 (2013)
- Atkinson TP, "Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections", FEMS Microbiol Rev, 32, pp.956~973 (2008)
- Miyashita N, "Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults", J Infect Chemother, 21, pp.153~160 (2015)
- 신정은, "Increased risk of refractory Mycoplasma pneumoniae pneumonia in children with atopic sensitization and asthma", Korean Journal of Pediatrics, 57(6), pp.271~277 (2014), 대한소아과학회
- Waites KB, "New concepts of Mycoplasma pneumoniae infections in children", Pediatr Pulmonol, 36, pp.267~278 (2003)
- Kawai Y, "Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients", Respirology, 17, pp.354~362 (2012)
- Chan ED, "Fulminant Mycoplasma pneumoniae pneumonia", West J Med, 162, pp.133~142 (1995)
- Lee KY, "Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children", Pediatr Pulmonol, 41, pp.263~268 (2006)
- Miyashita N, "Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit", J Med Microbiol, 56(Pt 12), pp.1625~1629 (2007)
- Radisic M, "Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment", Clin Infect Dis, 31, pp.1507~1511 (2000)
- Tamura A, "Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children", J Infect, 57, pp.223~228 (2008)
- 정혜원, "Mycoplasma pneumoniae 특이 항체검사에서 입자응집법과 효소면역 측정법의 비교", Laboratory Medicine Online, 2(1), pp.41~46 (2012), 대한진단검사의학회
- Peuchant O, "Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis", J Antimicrob Chemother, 64, pp.52~58 (2009)
- Averbuch D, "Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010", Emerg Infect Dis, 17, pp.1079~1082 (2011)
- Chironna M, "Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children", J Antimicrob Chemother, 66, pp.734~737 (2011)
- Kawai Y, "Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients", Antimicrob Agents Chemother, 57, pp.4046~4049 (2013)
- Okada T, "Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children", Clin Infect Dis, 55, pp.1642~1649 (2012)
- Yamada M, "Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States", Pediatr Infect Dis J, 31, pp.409~411 (2012)
- Zheng X, "Macrolide-resistant Mycoplasma pneumoniae, United States", Emerg Infect Dis, 21, pp.1470~1472 (2015)
- Bébéar C, "Mycoplasma pneumoniae: susceptibility and resistance to antibiotics", Future Microbiol, 6, pp.423~431 (2011)
- Luo Z, "Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children", Pediatr Pulmonol, 49, pp.377~380 (2014)
- Yoo SJ, "Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance", Antimicrob Agents Chemother, 56, pp.6393~6396 (2012)
- Youn YS, "Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia", BMC Pediatr, 10, pp.48~ (2010)
- 윤유숙, "Early Additional Immune-Modulators for Mycoplasma pneumoniae Pneumonia in Children: An Observation Study", Infection and Chemotherapy, 46(4), pp.239~247 (2014), 대한감염학회[DOI]
- Wang M, "Clinical and laboratory profiles of refractory Mycoplasma pneumoniae pneumonia in children", Int J Infect Dis, 29, pp.18~23 (2014)
- Inamura N, "Management of refractory Mycoplasma pneumoniae pneumonia: utility of measuring serum lactate dehydrogenase level", J Infect Chemother, 20, pp.270~273 (2014)